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ORIGINAL RESEARCH
Outcomes of Rescue Endovascular 
Treatment of Emergent Large Vessel 
Occlusion in Patients With Underlying 
Intracranial Atherosclerosis: Insights From 
STAR
Sami Al Kasab , MD*; Eyad Almallouhi , MD*; Ali Alawieh , MD, PhD; Stacey Wolfe, MD;  
Kyle M. Fargen, MD; Adam S. Arthur, MD; Nitin Goyal, MD; Travis Dumont, MD; Peter Kan, MD; Joon- Tae Kim , MD; 
Reade De Leacy, MD; Ilko Maier , MD; Joshua Osbun, MD; Ansaar Rai, MD; Pascal Jabbour , MD; 
Jonathan A. Grossberg , MD; Min S. Park, MD; Robert M. Starke, MD; Roberto Crosa , MD;  
Alejandro M. Spiotta, MD; on behalf of STAR collaborators†
BACKGROUND: Some emergent large vessel occlusions (ELVOs) are refractory to reperfusion because of underlying intracranial 
atherosclerosis (ICAS), often requiring rescue therapy (RT) with balloon angioplasty, stenting, or both. In this study, we inves-
tigate the safety, efficacy, and long- term outcomes of RT in the setting of mechanical thrombectomy for ICAS- related ELVO.
METHODS AND RESULTS: We queried the databases of 10 thrombectomy- capable centers in North America and Europe in-
cluded in STAR (Stroke Thrombectomy and Aneurysm Registry). Patients with ELVO who underwent ICAS- related RT were 
included. A matched sample was produced for variables of age, admission National Institute of Health Stroke Scale, Alberta 
Stroke Program Early CT Score, onset to groin puncture time, occlusion site, and final recanalization. Out of 3025 patients 
with MT, 182 (6%) patients required RT because of underlying ICAS. Balloon angioplasty was performed on 122 patients, and 
117 patients had intracranial stenting. In the matched analysis, 141 patients who received RT matched to a similar number of 
controls. The number of thrombectomy passes was higher (3 versus 1, P<0.001), and procedural time was longer in the RT 
group (52 minutes versus 36 minutes, P=0.004). There was a higher rate of symptomatic hemorrhagic transformation in the RT 
group (7.8% versus 4.3%, P=0.211), however, the difference was not significant. There was no difference in 90- day modified 
Rankin scale of 0 to 2 (44% versus 47.5%, P=0.543) between patients in the RT and control groups.
CONCLUSIONS: In patients with ELVO with underlying ICAS requiring RT, despite longer procedure time and a more thrombec-
tomy passes, the 90 days favorable outcomes were comparable with patients with embolic ELVO.
Key Words: acute stroke ■ balloon angioplasty ■ intracranial atherosclerosis ■ mechanical thrombectomy ■ rescue therapy ■ stenting
Mechanical thrombectomy (MT) is the standard of care for patients with emergent large vessel occlusion (ELVO) and salvageable brain tissue.1 Outcomes following MT depend primarily on achieving fast and successful revascularization.2,3 Approximately 10% to 20% of patients undergoing MT, however, fail 
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to achieve successful revascularization.4– 6 Etiology for 
unsuccessful revascularization can be divided into ei-
ther failure to access the intracranial vasculature or in-
ability to achieve successful revascularization despite 
successful access to the intracranial vasculature. In 
the latter, the most common reason for revascular-
ization failure following successful intracranial access 
is underlying intracranial atherosclerosis (ICAS), ren-
dering the vessel with fixed severe residual stenosis 
or in- situ thrombosis with instant reocclusion despite 
multiple attempts, with other causes including in-
tracranial dissection, or iatrogenic perforation being 
much less common.7,8 While management of patients 
with ICAS presenting with a transient ischemic at-
tack or stroke within 30  days has been established 
with evidence from large, randomized controlled tri-
als showing that medical management is superior to 
angioplasty and/or stenting,9,10 acute management of 
ICAS- related ELVO is unclear and poses a major chal-
lenge. Patients with ICAS- related ELVO often require 
rescue therapy (RT) with angioplasty, stenting, or both 
to achieve successful revascularization. Few previous 
studies have evaluated the safety of RT in patients with 
ELVO with failed reperfusion because of underlying 
ICAS. Most of these studies had small sample size 
and were mostly performed in Asia, which limits their 
applicability to the Western patient population given 
that outcomes of ICAS in patients with transient isch-
emic attack and ischemic stroke are different between 
Asian and Western countries.10– 12 The aim of this study 
is to investigate the frequency of ICAS in the setting 
of mechanical thrombectomy and assess the safety, 
efficacy, and long- term outcomes associated with RT 
with angioplasty and/or stenting following failed reper-
fusion in a large multicenter cohort in the United States 
and Europe.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request. We used data from the prospectively 
maintained databases of 10 thrombectomy- capable 
stroke centers in North America, and Europe in-
cluded in STAR (Stroke Thrombectomy and Aneurysm 
Registry). Informed consent was waived. In this analy-
sis, we included patients who underwent mechanical 
thrombectomy using approved second- generation 
thrombectomy devices from June 2013 through 
December 2019.
We evaluated the rate of RT with angioplasty and/
or stenting secondary to presumed ICAS (ICAS RT 
group) during mechanical thrombectomy for ELVO. 
Initial angiographic images showed complete oc-
clusion in the included patients with thrombectomy. 
Following thrombectomy, patients who had fixed re-
sidual stenosis (50%– 99%) or instant intraoperative 
reocclusion requiring RT were considered as patients 
with ICAS RT. This definition has been validated in 
multiple previous studies.8,13,14 Patients who received 
RT for reasons other than presumed ICAS were ex-
cluded from our analyses. Collected data included 
baseline demographics, vascular risk factors, and 
admission National Institute of Health Stroke Scale 
(NIHSS), whether or not patients received intrave-
nous alteplase (tPA), time from symptom onset to 
groin puncture, procedural times in minutes, throm-
bectomy techniques, number of attempts, whether 
angioplasty and/or stenting was performed, type of 
CLINICAL PERSPECTIVE
What Is New?
• In our observational multicenter study, ≈6% of 
patients with intracranial atherosclerosis (ICAS) 
who had mechanical thrombectomy underwent 
also rescue therapy with angioplasty/stenting.
• Compared with patients with non- ICAS, pa-
tients with ICAS rescue therapy required longer 
procedure time and more thrombectomy 
passes compared with patients with mechani-
cal thrombectomy who did not require rescue 
therapy; however, there was no statistically sig-
nificant difference in symptomatic hemorrhagic 
transformation or 90- day outcome after match-
ing for key characteristics including final reper-
fusion status.
What Are the Clinical Implications?
• Our observational study suggests a benefit for 
rescue therapy with angioplasty/stenting in pa-
tients with underlying ICAS evident during me-
chanical thrombectomy.
• Further randomized studies are needed to more 
definitively answer whether angioplasty/stenting 
in patients with ICAS is beneficial.
Nonstandard Abbreviations and Acronyms
ASPECTS Alberta Stroke Program Early CT 
Score
ELVO emergent large vessel occlusion
ICAS intracranial atherosclerosis
MT mechanical thrombectomy
NIHSS National Institute of Health Stroke 
Scale
RT rescue therapy
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stent used, complication rates, and rate of symptom-
atic hemorrhage.
Successful revascularization was defined as 
modified thrombolysis in cerebral infarction of 2b- 3. 
Symptomatic hemorrhagic transformation (sICH) was 
defined using ECAS III (European Cooperative Acute 
Stroke Study) definition (worsening of ≥4 points in 
NIHSS attributed to hemorrhagic transformation),15 and 
favorable long- term functional outcome was defined 
as modified Rankin scale of 0 to 2 at 90 days.
Statistical Analysis
Descriptive statistics were used to report patient demo-
graphic and clinical characteristics using median and 
interquartile range (IQR) for continuous variables and 
percentages for categorical variables. Characteristics 
of groups were compared using the Wilcoxon rank- 
sum (Mann- Whitney) test and Chi- square (or Fisher 
exact test for cells <5) as appropriate. An alpha level 
of 0.05 was used as the level of statistical significance. 
We assessed the predictors of receiving RT during 
MT using a logistic regression model controlling for 
age, sex, race, stroke risk factors (diabetes mellitus, 
hypertension, atrial fibrillation, hyperlipidemia), Alberta 
Stroke Program Early Computerized Tomography (CT) 
Score (ASPECTS) on admission, baseline NIHSS, loca-
tion of occlusion, and onset to groin time. To determine 
predictors of favorable outcomes in patients in the 
ICAS RT group, we used a logistic regression model 
controlling for age, sex, race, and baseline NIHSS, lo-
cation of occlusion, rescue technique used, and final 
recanalization score.
To evaluate outcomes of patients with ICAS RT, a 
control group sample of patients with MT with em-
bolic ELVO was produced by matching the follow-
ing variables: age, onset to groin time, admission 
NIHSS, location of the occlusion, and final modified 
thrombolysis in cerebral infarction score. The cen-
ter that procedure was done at was used in addi-
tion to the previously mentioned variables to match 
another control group (Table S1). We used Wilcoxon 
rank- sum (Mann- Whitney) test and Chi- square (or 
Fisher exact test for cells <5) to compare baseline 
features (age, sex, race, stroke risk factors, admis-
sion NIHSS, use of IV- tPA, ASPECTS on admission 
and location of occlusion), procedural variables (time 
from symptom onset to groin puncture, procedure 
duration, final modified thrombolysis in cerebral in-
farction score, number of passes and complications) 
and outcomes, sICH, 90- day mortality and 90- day 
modified Rankin scale between matched ICAS RT 
patients and the control groups.
To ensure the robustness of our results, we 
performed sensitivity analysis using a binary logis-
tic regression model to assess: (1) the association 
between RT and favorable 90- day outcome in pa-
tients who achieved successful recanalization, (2) the 
relationship between RT and 90- day mortality in pa-
tients who had unsuccessful recanalization. Our sen-
sitivity model was derived with inverse probability of 
treatment weight using propensity scores. The pro-
pensity scores were calculated using a binary logistic 
regression model for ICAS RT adjusting for age, sex, 
race, stroke risk factors, ASPECTS on admission, 
baseline NIHSS, location of occlusion, and onset to 
groin time. Covariates in the propensity score model 
that have a <0.20 standardized difference before 
and after weighting were considered well- matched. 
Finally, we introduced the center variable to both re-
gression models.
All final models were tested for collinearity. The anal-
ysis was conducted using SPSS v25 (IBM Corporation, 
New York, NY) with Fuzzy extension v1.
Institutional Review Board Approval
The study was approved by the Institutional Review 
Board at each of the included centers.
RESULTS
RT Group
Total of 3025 patients underwent mechanical 
thrombectomy in the included centers. Of those, 
189 patients received intracranial rescue angioplasty, 
stenting, or both during MT for ELVO. Seven patients 
were excluded because of dissection being the rea-
son for RT, leaving 182 who met ICAS- related ELVO 
criteria. Table  1 summarizes the baseline features of 
patients included in the study. Compared with patients 
with embolic ELVO, patients in the ICAS RT group 
were younger (age 67 versus 71 years, P=0.004), more 
likely to have diabetes mellitus (36.8% versus 28.5%), 
more likely to have hyperlipidemia (51.1% versus 37%), 
and less likely to have atrial fibrillation (16.5% versus 
35.3%) compared with other patients with MT. Median 
NIHSS on admission was 14 (IQR, 9– 20), and median 
ASPECTS was 9 (IQR, 7– 10) in the ICAS RT group. 
On multivariate analyses after adjusting for potential 
confounders, predictors for RT secondary to ICAS 
were diabetes mellitus (odds ratio [OR], 1.49; 95% CI, 
1.03– 2.17; P=0.035), hyperlipidemia (OR, 1.92; 95% CI, 
1.33– 2.78; P=0.001), and onset to groin time (OR, 1.03; 
95% CI, 1.01– 1.05; P=0.003), while atrial fibrillation was 
associated with lower odds of requiring RT (OR, 0.34; 
95% CI, 0.23– 0.58; P<0.001).
In terms of thrombectomy technique before RT, as-
piration only was used in 107 patients; stent retriever in 
37 patients, "Solumbra" (combined stent- retriever and 
aspiration) in 13 patients, and the remaining 25 pa-
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of thrombectomy passes before RT was 3 (IQR, 2– 4). 
In terms of type of RT used, 65 patients required an-
gioplasty alone, 60 patients required stenting alone, 
and 57 patients required both. Intra- arterial tPA before 
RT was used in 19 (10.4%) of the 182 patients. The 
approach to RT was dependent on the interventionist, 
angioplasty was first attempted in cases with residual, 
fixed stenosis, and a stent was placed if re- stenosis 
occurred. In cases of in- situ thrombosis, a follow up 
angiography was typically performed at 3 to 10 min-
utes interval and if reocclusion occurred, a stent was 
placed. Patients who received intravenous tPA were 
less likely to get stented (P=0.015). In the tPA group, 
stenting was performed in 33 patients (52.4%) versus 
84 (70.6%) in the non- tPA group. The specific stent 
type was available for 69 of 117 patients. Neuroform 
Atlas (Stryker Neurovascular, Fremont, USA) stent was 
used in 41, Wingspan stent was used (Stryker) in 12 
cases, balloon mounted stents were used in 10, of 
those 7 were resolute integrity stents (Medtronic Inc. 
Santa Rosa, CA, USA) and 3 were multilink stents 
(Multilink Duet, Guidant Corporation, Inc.), and 6 cases 
were LVIS Jr (Microvention, CA, USA) stents. The an-
tiplatelet regimen used was available for 99 of 117 
who underwent stenting; 97 patients received weight 
based tirofiban, eptifibatide, or abciximab loading 
dose depending on local institution protocol followed 
by continuous infusion for 6 hours, and loading doses 
of 650 mg aspirin and 600 mg clopidogrel (no load-
ing dose was used for patients already on aspirin and/
or clopidogrel before presentation), followed by daily 
dose of aspirin 325 mg and clopidogrel 75 mg. Two 
patients received heparin infusion followed by aspirin 
and clopidogrel loading and daily maintenance doses.
The sICH occurred in 15 (8.2%) patients, and 69 
(37.9%) patients achieved favorable long- term func-
tional outcome at 90  days (modified Rankin scale, 
0– 2). Among patients who received a stent, 9 of 117 
(7.7%) patients had sICH (2 received intravenous tPA 
and 7 did not receive tPA, P=0.678). On multivariate 
analysis, rescue technique was not an independent 
predictor for favorable 90  days outcomes (OR, 0.72; 
95% CI, 0.47– 1.09; P=0.120) after controlling for age, 
sex, race, location of occlusion, NIHSS on admission, 
and final recanalization score.
Matched Analysis
We matched 141 patients from the ICAS RT group 
with the same number of patients with MT who have 
similar age, admission NIHSS, location of the occlu-
sion, onset to groin time, and revascularization sta-
tus. Table  2 presents baseline features, procedural 
metrics, and outcomes in the 2 treatment groups. 
Table 1. Baseline Features and Outcomes of Patients Who Underwent Rescue Therapy for Presumed Intracranial 
Atherosclerotic Disease
Rescue Therapy Group (n=182) Non- Rescue Therapy Group (n=2843) P Value*
Age, median (IQR) 67 (59– 76) 71 (60– 80) 0.004†
Women, n (%) 82 (45.1) 1410 (49.6) 0.235
White, n (%)‡ 106 (58.2) 1442 (61.8) 0.341
Hypertension, n (%) 140 (76.9) 2074 (73) 0.241
DM, n (%) 67 (36.8) 811 (28.5) 0.017†
AF, n (%) 30 (16.5) 1004 (35.3) <0.001†
Hyperlipidemia , n (%) 93 (51.1) 1053 (37) <0.001†
Prior stroke, n (%) 28 (15.4) 243 (8.5) 0.002†
Admission NIHSS, median (IQR) 14 (9– 20) 15 (10– 20) 0.432
IV- tPA, n (%) 63 (34.6) 1409 (49.6) <0.001†
ASPECTS, median (IQR) 9 (7– 10) 9 (7– 10) 0.731
Posterior circulation, n (%) 29 (15.9) 324 (11.4) 0.064
Onset to groin in min, median (IQR) 341 (215– 626) 240 (150– 381) <0.001†
No. of passes, median (IQR) 3 (2– 4) 2 (1– 3) <0.001†
mTICI ≥2b, n (%) 151 (83) 2199 (77.3) 0.078
Procedure duration in min, median 
(IQR)
52 (29– 94) 42 (23– 73) 0.003†
Peri- procedural complications, n (%) 13 (7.1) 190 (6.7) 0.81
AF indicates atrial fibrillation; ASPECTS, Alberta Stroke Program Early Computerized Tomography (CT) Score; DM, diabetes mellitus; IQR, interquartile range; 
IV- tPA, intravenous tissue plasminogen activator; mTICI, modified thrombolysis in cerebral infarction; and NIHSS, National Institute of Health Stroke Scale.
*Calculated using χ2 for categorical variables and Wilcoxon test for the continuous variables.
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There was no difference in age, race, or sex between 
the 2 groups. More patients in the control group 
had atrial fibrillation (70 [43.5%] versus 20 [12.4%], 
P<0.001). Other stroke risk factors (diabetes melli-
tus, hypertension, hyperlipidemia, and prior stroke) 
were balanced between both groups. There was no 
difference in admission NIHSS, ASPECT score on 
admission, location of occlusion, or time from symp-
tom onset to groin puncture (Table 2). Patients in the 
control group had a lower number of thrombectomy 
passes (1 [IQR, 1– 2] versus 3 [IQR, 2– 4], P<0.001). Of 
the 141 patients, balloon angioplasty was performed 
in 49 patients, stenting was performed in 46 patients, 
and 46 patients underwent both angioplasty and 
stenting. Patients in the ICAS RT group had longer 
procedure duration (52 [IQR, 28– 92] versus 36 [25– 
59] minutes, P=0.004). There was no difference in the 
rate of sICH between the 2 groups (11 [7.8%] in the 
ICAS RT group versus 5 [4.3%] in the control group, 
P=0.211) (Table  S1 compares the rate of sICH in 
anterior versus posterior circulation). Finally, no sta-
tistically significant difference was found in the rate 
of favorable 90- day functional outcome (62 [44%] 
versus 67 [47.5%], P=0.55), and 90- day mortality 
(32 [22.7%] versus 41 [29.1%], P=0.221) in the ICAS 
RT group compared with the control group. Figure 
shows the distribution of 90- day modified Rankin 
scale in the patients in the matched analysis.
Sensitivity Analysis
On the logistic regression analysis with inverse prob-
ability of treatment weight and propensity score, re-
ceiving RT secondary to ICAS was not an independent 
predictor of favorable 90- day outcomes (OR, 0.82; 
95% CI, 0.55– 1.24; P=0.351) in patients who achieved 
successful recanalization. In addition, receiving RT 
secondary to ICAS was not an independent predic-
tor of 90- day mortality (OR, 1.54; 95% CI, 0.86– 7.53, 
P=0.094) in patients who had failed recanalization. 
After introducing the center variable, it was not a sta-
tistically significant predictor in either of the models 
(P>0.999).
DISCUSSION
To our knowledge, our multicenter study is the larg-
est to date to provide safety and long- term outcome 
data on patients undergoing mechanical thrombec-
tomy for ELVO because of underlying ICAS requir-
ing rescue angioplasty, stenting, or both. Our study 
shows that ≈6% of patients undergoing MT have un-
derlying ICAS and require RT with angioplasty and/
or stenting. In terms of procedural metrics, our study 
shows that patients with ICAS- related ELVO require 
longer procedural times and a higher number of 
thrombectomy passes compared with patients with 
embolic ELVO. Also, compared with patients with 
embolic ELVO, patients receiving RT had numerically 
higher rates of sICH, though this was not statistically 
significant. Nevertheless, there was no difference in 
90- day functional outcomes in the RT group.
Intracranial atherosclerosis- related emergent 
large vessel occlusion poses a major challenge to 
endovascular thrombectomy. The major challenge of 
ICAS- related ELVO is the tendency of intra- procedural 
in- situ reocclusion or cause a residual, fixed severe 
Table 2. Baseline Features, Procedural Metrics, and 







Group (n=141) P Value*
Age, median (IQR) 67 (60– 76) 68 (59– 78) 0.522
Women, n (%) 65 (46.1) 67 (47.5) 0.811
White, n (%) 101 (71.6) 108 (76) 0.341
Hypertension, n (%) 109 (77.3) 115 (81.6) 0.377
DM, n (%) 54 (38.3) 43 (30.5) 0.168
AF, n (%) 20 (14.2) 50 (35.5) <0.001†
Hyperlipidemia, 
n (%)
71 (50.4) 66 (46.8) 0.551
Prior stroke, n (%) 20 (14.2) 10 (7.1) 0.053
Admission NIHSS, 
median (IQR)
14 (9– 20) 14 (10– 19) 0.838
IV- tPA, n (%) 56 (39.7) 67 (47.5) 0.187
ASPECTS, median 
(IQR)
8 (7– 9) 8 (7– 9) 0.731
Posterior circulation 
stroke, n (%)
16 (11.3) 16 (11.3) >0.999
Onset to groin in 
min, median (IQR)
310 (206– 525) 303 (207– 542) 0.804
No. of passes, 
median (IQR)
3 (2– 4) 1 (1– 2) <0.001†
mTICI ≥2b, n (%) 124 (87.9) 124 (87.9) 1
Procedure duration 
in min, median (IQR)
52 (28– 92) 36 (25– 59) 0.004†
Peri- procedural 
complications, n (%)
12 (8.5) 10 (7.1) 0.227
sICH, n (%) 11 (7.8) 6 (4.3) 0.211
90- d mRS, median 
(IQR)
3 (1– 5) 3 (1– 6) 0.543
Favorable 90- d 
outcomes, n (%)
62 (44) 67 (47.5) 0.55
90- d mortality 32 (22.7%) 41 (29.1%) 0.221
AF indicates atrial fibrillation; ASPECTS, Alberta Stroke Program Early 
Computerized Tomography (CT) Score; DM, diabetes mellitus; IQR, 
interquartile range; IV- tPA, intravenous tissue plasminogen activator; mRS, 
modified Rankin scale; mTICI, modified thrombolysis in cerebral infarction; 
NIHSS, National Institute of Health stroke scale; and sICH, symptomatic 
hemorrhagic transformation.
*Calculated using χ2 test for categorical variables and Wilcoxon test for the 
continuous variables.
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stenosis rendering the vessel with suboptimal revas-
cularization.16 It is estimated that reocclusion occurs 
in approximately one third of patients with ICAS- 
related ELVO, compared with 2.7% in patients with 
embolic ELVO.14 The exact pathophysiology behind 
this is unclear; however, postmortem studies sug-
gest fibrous cap disruption and sub- intimal dissec-
tion and in- situ thrombosis of the involved vessel 
as the potential reason for reocclusion.17 A study by 
Kang et al, evaluated the rate of instant reocclusion 
during MT, in their study, 40 of 132 (30%) had in situ 
thrombosis with reocclusion, and all of those patients 
had underlying ICAS on follow- up imaging.8 Given 
the known risks associated with intracranial angio-
plasty and stenting in patients with ischemic stroke, 
the interventionist is often left with a dilemma of ei-
ther leaving the affected vessel occluded which often 
results in disabling stroke or acutely perform angio-
plasty and/or stenting. The risk- benefit profile how-
ever is different when managing patients with ICAS 
with ELVO compared with those without ELVO for 
whom the benefit of angioplasty with/without stent-
ing doesn’t outweigh the associated risks.9,10 Our 
study shows that patients with ICAS- related ELVO 
requiring rescue angioplasty and/or stenting were 
able to achieve comparable long- term outcomes 
compared with patients with embolic ELVO with sim-
ilar safety profile even after requiring RT. A possible 
explanation to the good outcome in this group is that 
patients with ICAS have better collateral circulation 
compared with patients with embolic ELVO, therefore 
lower baseline infarct volume.18 Moreover, a study 
by Suh et al found that baseline infarct volume was 
lower in patients with ICAS- related ELVO compared 
with embolic ELVO (14 versus 54 mL, P<0.001).19
A number of studies have evaluated the safety and 
efficacy of angioplasty, stenting, or both stenting as a 
rescue technique in the setting of ELVO and underlying 
ICAS. Most of these studies were limited by small sam-
ple size. Furthermore; the vast majority of these studies 
were performed in Asia with only few studies coming 
from the United States and Europe.10,20 Aside from ICAS 
being more common in Asian patient population, simi-
lar to ICAS in the non- emergent setting, studies coming 
from the United States and Europe have shown differ-
ent results compared with those coming from Asia.10– 12 
While it remains unclear why there are such stark differ-
ences in treatment effects between Asian and Western 
Figure 1. The distribution of 90- day modified Rankin scale in the rescue therapy secondary to 
intracranial atherosclerosis group compared with the control group.
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patient populations with ICAS, studies have suggested 
genetic, socioeconomic, and dietary differences as con-
tributing factors.21,22 A study done in Korea by Yoon et 
al evaluated the safety of emergent angioplasty with or 
without stenting in patients with ICAS- related ELVO, the 
authors reported more favorable outcomes in the ICAS 
group compared with the control group with no differ-
ence in symptomatic intracranial hemorrhage, or mor-
tality.23 Conversely, a study from Spain by Matias- Guiu 
reported longer procedural times; higher mortality and 
lower rates of good functional outcomes in ICAS- related 
ELVO requiring RT with angioplasty with or without 
stenting.24 This study, however, only had 15 patients with 
ICAS.25,26 Other studies reporting on comparably small 
sample sizes performed in the United States and Europe 
have reported conflicting results with regards to rates 
of successful revascularization, complication rates, and 
long- term outcomes.16 The small sample size in those 
studies is likely attributable to the fact that ICAS is less 
prevalent in Western compared with Asian population.27
Our findings support a 2019 systematic review and 
meta- analysis conducted by Chun On Tsang et al that 
reported higher prevalence of hypertension, hyperlip-
idemia, and diabetes mellitus and lower atrial fibrillation 
in patients with ICAS- related ELVO.16 In our study, hy-
perlipidemia and diabetes mellitus were independent 
predictors of requiring RT for ICAS. Similarly, our study 
supports the findings of this meta- analysis demon-
strating longer procedural times and similar rates of 
final successful revascularization and sICH. Our study, 
however, only included patients in the United States 
and Europe, and therefore provides evidence support-
ing the safety and efficacy of rescue angioplasty and/
or stenting in patients with ICAS- related ELVO in non- 
Asian patient population.
It is important to point out that while our study 
shows that rescue angioplasty and/or stenting in 
the setting of ICAS- related ELVO, the optimal rescue 
technique is patients with failed MT secondary to re-
occlusion or fixed stenosis remains uncertain, and 
the approach to such patients varies by center. In our 
study, we found that angioplasty alone can be effec-
tive in up to one third of patients, it is important, how-
ever, to keep in mind that among the 122 patients who 
underwent angioplasty, 57 patients (47%) eventually 
required stenting. Importantly, the type of stent used 
varied by center, and the most commonly used stents 
were self- expandable stents. A recent study by Gross 
et al suggests the use of balloon- mounted stents given 
higher radial force, in this study however, patients un-
dergoing stenting with balloon- mounted stents had 
higher rates of sICH and mortality.28 Of note, our study 
did not show a correlation between stenting and sICH 
in patients who have already received intravenous tPA.
In this study, we presented the outcomes of using 
stenting, angioplasty, or both as an RT but other 
rescue techniques have become available recently 
including intra- arterial infusion of antiplatelet, such as 
Tirofiban or Abxicimab. A recent study performed in 
Korea compared the outcomes of using intra- arterial 
glycoprotein IIb/IIIa inhibitor infusion and emergent an-
gioplasty found that both techniques resulted in a suc-
cessful revascularization rate of about 95% with similar 
rates of symptomatic hemorrhage, 3- month functional 
independence and mortality.29 However, the study 
was limited by major differences in baseline and pro-
cedural characteristics which could have influenced 
the results. Nevertheless, such new treatments appear 
less invasive and need to be compared with rescue 
angioplasty/stenting.
Strength and Limitations
The main strength of our study is the inclusion of large 
cohort derived from the real- world daily practice in dif-
ferent countries in North America and Europe. On the 
other hand, some limitations of our work must be ac-
knowledged. First, the retrospective design, the lack 
of randomization, and potential residual confounders 
should be kept in mind when interpreting the results 
of our study. In addition, given lack of follow- up imag-
ing data, we couldn’t comment on stent patency and 
whether or not some of those patients had residual 
in stent stenosis. Furthermore, the specific devices, 
reperfusion approaches, stents used, intraprocedural 
sedation, and post- procedural blood pressure targets 
were heterogeneous and were selected according to 
the treating physicians’ preference. Also, data about 
collateral score are not available, and the safety and ef-
ficacy outcomes in different centers were self- reported 
without central adjudication.
CONCLUSIONS
Our multicenter study reports that there was no sta-
tistically significant difference in the 90- day outcomes 
in patients with ICAS RT who were treated with acute 
stenting, angioplasty, or both compared with a control 
group of patients with MT with embolic ELVO. Patients 
who require RT, however, had longer procedural times, 
and higher number of thrombectomy passes. Future 
randomized clinical trials are required to definitely eval-
uate the potential efficacy of RT with angioplasty and/
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Table S1. Baseline features, procedural metrics and outcomes in the 2 groups 
(rescue therapy vs. matched control) after matching for age, onset to groin time, 
admission NIHSS, location of the occlusion, final mTICI score, and the center 
that the procedure was done at. 





Age, median (IQR) 68 (61-75) 68 (60-76) 0.976 
Females, n (%) 36 (42.4%) 34 (40%) 0.755 
White, n (%) 49 (57.6%) 55 (64.7%) 0.345 
HTN, n (%) 62 (72.9%) 59 (69.4%) 0.611 
DM, n (%) 29 (34.1%) 25 (29.4%) 0.51 
Afib, n (%) 12 (14.1%) 29 (34.1%) 0.002 
HLD, n (%) 37 (43.5%) 34 (40%) 0.641 
Prior stroke, n (%) 8 (9.4%) 4 (4.7%) 0.231 
Admission NIHSS, 
median (IQR) 15 (10-20) 16 (11-20) 0.687 
IV-tPA, n (%) 43 (50.6%) 43 (50.6%) >0.999 
ASPECTS, median 
(IQR)  9 (7-10) 8 (7-10) 0.534 
Posterior 
circulation stroke, 
n (%) 4 (4.7%) 4 (4.7%) >0.999 
Onset to groin in 
minutes, median 
(IQR) 288 (187-451) 291 (200-445) 0.924 
Number of 
passes, median 
(IQR) 3 (2-5) 2 (1-4) 0.09 
mTICI≥2b, n (%) 77 (90.6%) 77 (90.6%) >0.999 
Procedure 










(%) 1 (1.2%) 1 (1.2%) >0.999 
sICH, n (%) 6 (7.1%) 9 (10.6%) 0.417 
90-day mRS, 
median (IQR) 2 (1-4) 2 (1-4) 0.825 
Favorable 90-day 
outcomes, n (%) 44 (51.8%) 48 (56.5%) 0.538 
90-day mortality 17 (20%) 11 (12.9%) 0.215 
 
 
Afib: atrial fibrillation, ASPECT: Alberta Stroke Program Early CT, DM: Diabetes, HLD: 
hyperlipidemia, HTN: hypertension, IV-tPA: intravenous tissue plasminogen activator, 
mRS: modified Rankin scale, mTICI: modified Thrombolysis in Cerebral Infarction, 
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